title: Vitiligo in a patient receiving infliximab for refractory ulcerative colitis.
abstract: Infliximab is a chimerical monoclonal antibody that inhibits pro-inflammatory activity of tumour-necrosis factor alpha (TNFα) and it is the primary biological agent used in the treatment of moderate-to-severe ulcerative colitis (UC). We report a case of vitiligo following infliximab administration in a patient with refractory UC. The case serves as a reminder of adverse cutaneous reactions induced by TNFα-antagonist therapy.
authors.affiliation: Department of Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt. waleed.fattah@yahoo.com
authors.forename: Waleed A
authors.initials: WA
authors.lastname: Ismail
authors.forename: Saleh A
authors.initials: SA
authors.lastname: Al-Enzy
authors.forename: Saqer A
authors.initials: SA
authors.lastname: Alsurayei
authors.forename: Ali E
authors.initials: AE
authors.lastname: Ismail
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D014820:Vitiligo / Q000139:chemically induced*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab